Results 101 to 110 of about 10,588 (253)

Second Korean guidelines for the management of ulcerative colitis [PDF]

, 2017
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during ...
���������
core   +1 more source

Distal Ulcerative Colitis Refractory to Rectal Mesalamine: Role of Transdermal Nicotine versus Oral Mesalamine

Canadian Journal of Gastroenterology, 2002
BACKGROUND: Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly defined.AIM: To evaluate the possible therapeutic benefit of transdermal nicotine versus oral mesalamine.PATIENTS AND METHODS: Thirty patients with left-sided ulcerative colitis unresponsive to treatment with a ...
Guslandi M, Frego R, Viale E, TESTONI , PIER ALBERTO   +3 more
openaire   +5 more sources

Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials

Drug Design, Development and Therapy, 2014
David Pierce,1 Mary Corcoran,2 Patrick Martin,2 Karen Barrett,1 Susi Inglis,1 Peter Preston,2 Thomas N Thompson,3 Sandra K Willsie3 1Shire, Basingstoke, UK; 2Shire, Wayne, PA, USA; 3PRA International, Lenexa, KS, USA Background: MMX® mesalamine is a
Pierce D, Corcoran M, Martin P, Barrett K, Inglis S, Preston P, Thompson TN, Willsie SK   +7 more
doaj  

Chemoprevention with a tea from hawthorn (Crataegus oxyacantha) leaves and flowers attenuates colitis in rats by reducing inflammation and oxidative stress

Food Chemistry: X, 2021
The purpose of the study was to determine the effects of a tea from the leaves and flowers of Crataegus oxyacantha in rats with colitis. Colitis was induced by administration of 2,4,6-trinitrobenzene sulfonic acid. Hawthorn tea (HT) (100 mg/kg) was given
Roberto de Paula do Nascimento, Ana Paula da Fonseca Machado, Verena Silva Lima, Amanda Maria Tomazini Munhoz Moya, Lívia Mateus Reguengo, Stanislau Bogusz Junior, Raquel Franco Leal, Phu Cao-Ngoc, Jean Christophe Rossi, Laurent Leclercq, Hervé Cottet, Cinthia Baú Betim Cazarin, Mario Roberto Marostica Junior   +12 more
doaj  

2083 Mesalamine-Induced Myocarditis

American Journal of Gastroenterology, 2019
INTRODUCTION: Mesalamine is a widely used medication for treatment in patients with ulcerative colitis (UC). A rare adverse effect (AE) is mesalamine-induced myocarditis (MIM). A high index of suspicion is essential for prompt diagnosis and prevention of significant morbidity.
Kambiz Kadkhodayan, Tyler Putnam, Erica P. Turse   +2 more
openaire   +3 more sources

Mesalamine in pediatric inflammatory bowel disease: A 10-year experience [PDF]

, 1996
Ian D. DʼAgata, Tsafrir Vanounou, Ernest G. Seidman   +2 more
openalex   +1 more source

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report

Case Reports in Pediatrics, 2011
Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients.
Elimarys Perez-Colon, Gul H. Dadlani, Ivan Wilmot, Michelle Miller   +3 more
doaj   +1 more source

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

Cells, 2019
IBD98-M is a delayed-release formulation of mesalamine (mesalazine) and SH with a potential therapeutic role in ulcerative colitis (UC). A total of 51 patients with a modified Ulcerative Colitis Disease Activity Index (UCDAI) score of ≥4 and ≤
Gionata Fiorino, Giacomo Carlo Sturniolo, Fabrizio Bossa, Andrea Cassinotti, Antonio Di Sabatino, Paolo Giuffrida, Silvio Danese   +6 more
doaj   +1 more source

Mesalamine: Safe at first look [PDF]

Inflammatory Bowel Diseases, 1999
Jacqueline L. Wolf, Lawrence J. Saubermann   +1 more
openaire   +3 more sources

Mesalamine for the prevention of postoperative recurrence: Is nearly there the same as being there? [PDF]

, 2000
Lloyd R. Sutherland
openalex   +1 more source